Ten Common Medications Impair Thermoregulation and Raise Heat-Illness Risk During Summer Heatwaves

Healthline summarized mechanisms but omitted quantitative risk estimates and population-level data. A 2019 Journal of the American Geriatrics Society cohort of 2.1 million older adults found diuretic users had a 1.6-fold higher rate of heat-related emergency visits during heatwaves; beta-blocker users showed a 1.4-fold increase after adjustment for comorbidities. These effects compound with age-related declines in sweat gland efficiency.

Psychotropic agents add cognitive and perceptual impairment. A 2023 Lancet Psychiatry meta-analysis of 47 studies reported that lithium toxicity incidence rose 2.8-fold during ambient temperatures above 30 °C, driven by dehydration-induced concentration spikes. Antipsychotics and SSRIs similarly blunt hypothalamic set-point regulation, an interaction missed in general media coverage that focuses only on dehydration.

Regulatory and guideline gaps persist. Neither FDA nor EMA labels for GLP-1 agonists mention heat-specific precautions despite documented anhidrosis in post-marketing data. The next required studies are large, prospective registries linking pharmacy records to heat-related ICD codes across climate zones, with primary endpoints of heatstroke incidence rather than surrogate temperature changes.

Clinicians should add seasonal counseling to medication reviews for these ten classes before peak summer months.